====== Zalcitabine ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1BsDMEWA_ZX9DjrSgvUGBQPjFyly1-M4SbSh2A16YUoOmgnIyG/?limit=15&utm_campaign=pubmed-2&fc=20230524082701}}

Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a [[nucleoside]] analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.

===== Adverse events =====

The most common adverse events at the beginning of treatment are nausea and headache. More serious adverse events are peripheral neuropathy, which can occur in up to 33% of patients with advanced disease, oral ulcers, oesophageal ulcers, and, rarely, pancreatitis.

One of the [[Neuropathy]] associated with [[drug]]s used for [[Acquired immunodeficiency syndrome treatment]]

Zalcitabine(ddC; Hivid®): the least potent of the [[nucleoside]] analogs, therefore rarely used;
dose-related [[neuropathy]] can be severe and persistent. More common in patients with DM or [[didanosine]] treatment.